-
MsD anti-infection new drug of "Pharmaceutical Express" has been approved clinically in China for listing trilaciclib
Time of Update: 2021-01-19
subsidiary was approved by the hydrochloric acid bromoso injection drug registration certificate today, Lu anti-pharmaceutical issued a notice that the holding subsidiary Shandong Lu anti-pharmaceutical group Essett Co., Ltd. received the State Drug
-
"Pharmaceutical Express" Jiangsu announced the new crown vaccine procurement catalog MSD sell-off Mod...
Time of Update: 2021-01-07
December 3, 2020 / Medical Information List: BMS Odivo New Adaptive Disease Listing Application was accepted by CDE; Merca East sold Moderna shares; Henrenoli glycopeptide injection clinical trial approved; Stone Pharmaceutical Group "first
-
"Pharmaceutical Express" MSD two phase 3 clinical results positive IQVIA in the first three quarters of revenue of 8 billion plus.
Time of Update: 2020-10-30
drug for chronic kidney disease-related itching (CKD-aP). (Xinhua) -- On October 20, IN8bio Corp., formerly known as Incysus Therapeutics, announced that it had filed an IPO application with the Securities and Exchange Commission to raise $86
-
RNA therapy is again favored by large pharmaceutical companies. MSD and SGI have reached cooperation one after another
Time of Update: 2020-06-19
Retrieved July 9, 2019, from [2] skyhawk therapeutics announcements expansion of collaboration agreement with Biogen.
-
Research and development daily, Hengrui medicine, capecitabine tablet, ever commented that MSD insomnia therapy was approved
Time of Update: 2020-02-17
Hengrui pharmaceutical announced that its subsidiary, Ruishi biomedical, recently received the notice of clinical trial of shr0302 tablets approved and issued by the State Drug Administration.
-
The nmpa approved 51 anti epidemic material enterprises, MSD insomnia therapy, and approved
Time of Update: 2020-02-17
2020asco SITC announced the new plan; Qilu pharmaceutical "pregabalin capsule" will be approved as the first to pass the consistency evaluation Stardust is a randomized, multicenter, interventional phase 3B study.
-
MSD update belsomra label information
Time of Update: 2020-02-10
Recently, MSD company announced that the US FDA approved it to update the label information of belsomra (suvorexant), reflecting its clinical data in the treatment of insomnia symptoms in patients with mild to moderate Alzheimer's disease.
-
Weigh! MSD to split into two companies
Time of Update: 2020-02-06
The spin off of the new company will explore potential in the areas of women's health, over patented brands and bioequivalent drugs, especially in the areas of fertility and contraception, and pursue global leadership and sustainable growth.
-
Weigh! MSD to split into two companies
Time of Update: 2020-02-06
On February 5, MSD released its Q4 and full year financial report in 2019, and announced a major news that it has decided to split MSD into two growth companies!
-
Cooperation between Otsuka pharmaceutical and MSD in the development of KRAS inhibitors
Time of Update: 2020-01-07
Today, MSD announced that it will develop small molecule anticancer drugs, including KRAS inhibitors, in cooperation with Taiho and Astex of Otsuka pharmaceutical.
-
Where will the fastest growth of biopharmaceutical industry come from in 2020? Who is the biggest winner, AZ or MSD?
Time of Update: 2020-01-03
According to the data of evaluate Pharma, the report points out the biggest sales growth momentum of biopharmaceutical industry next year, and focuses on the companies that achieve this growth.
-
The world's first Ebola vaccine! Ervebo of MSD has been approved by FDA to prevent Zaire type Ebola virus!
Time of Update: 2019-12-21
December 21, 2019 / BIOON / - Merck & Co recently announced that the U.S
Food and Drug Administration (FDA) has approved the Ebola vaccine ervebo (rVSV ∆ g-zebov-gp
-
T cell amplifier + immunotherapy! Nit cooperates with MSD to evaluate the efficacy of hyeukin-7
Time of Update: 2019-12-13
December 13, 2019 / BIOON / -- neoimmunotech (NIT) is a clinical stage biopharmaceutical company focusing on the development of T-cell therapy
Recently, the company
-
MSD 2.7 billion US dollars for a new generation of in-process therapy
Time of Update: 2019-12-10
A total of 47 patients with recurrent / refractory B-cell cancer received different doses of ARQ 531.
-
Immunotherapy for bladder cancer! MSD keytruda treatment NMIBC in the United States into the priority review
Time of Update: 2019-12-07
The US FDA has accepted and granted priority review to a supplementary biologicals licensing application (SBLA) from keytruda, an anti-PD-1 therapy, Merck said recently
-
Immunotherapy for NMIBC! Key truda of MSD has entered the priority review in the United States!
Time of Update: 2019-12-04
December 4, 2019 / BIOON / -- cancer immunotherapy giant Merck & Co recently announced that the US FDA has accepted a supplementary biological product license application (SBLA
-
ADC drug giant cooperates with MSD in the first-line treatment of stage III bladder cancer
Time of Update: 2019-12-03
On December 2, Seattle genetics / Astaire announced a cooperation agreement with MSD to jointly carry out the clinical trial of enfortumab vedotin and keytruda in the first-line treatment of locally advanced or metastatic urothelial carcinoma.
-
Nowhere to buy it! MSD HPV vaccine Gardasil will not meet global demand until 2023
Time of Update: 2019-11-01
Until 2023, MSD's manufacturing plants will be able to fully meet the global demand for Gardasil, the HPV vaccine
What if there's no supply? MSD has started to borrow
-
Q3 report card of multinational pharmaceutical companies announced: MSD China soared 90% Pfizer performance reversed
Time of Update: 2019-10-31
Pfizer, whose performance in China fell by 20% in the second quarter, achieved positive growth through structural adjustment, new drug remedy and other measures.
-
Q3 performance of MSD! K pharmaceutical's single quarter revenue of US $3 billion in China increased by 90%
Time of Update: 2019-10-30
Keytruda's global sales in the third quarter were $3.07 billion, up 62% year-on-year, with a total of $7.973 billion in the first three quarters of 2019.
